Beranda › Penyakit Radang Usus › New York
Uji klinis Penyakit Radang Usus di New York
21 studi untuk Penyakit Radang Usus mencari peserta di lokasi di New York.
Kota di New York
Teks studi resmi (Bahasa Inggris)
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Ellipsis Research Group, Brooklyn
- Smart Medical Research - Jackson Heights, Jackson Heights
- Pioneer Clinical Research NY, New York
- dan 1 lainnya
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06598943Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
- Xencor Investigative Site, Albany
- Xencor Investigative Site, Rochester
Menerima pesertaFase 1/2Sukarelawan sehat diterima
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT06619990A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 037, New York
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-002, Albany
- Site US-016, Rochester
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07845487A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center, New York
- Icahn School of Medicine at Mount Sinai, New York
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05923073Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- dan 1 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Icahn School of Medicine at Mount Sinai, New York
Menerima pesertaFase 3
Usia 2 hingga 19 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT04844606A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
- Digestive Disease Medicine of Central New York, Utica
Menerima pesertaFase 4
3 Weeks · Wanita · Diperbarui 8 Sep 2026 · NCT07612267A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Weill Cornell Medical College (WCMC) - Judith Jaffe Multiple Sclerosis Center (JJMSC), New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center/New York Presbyterian, New York
Menerima pesertaFase 3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05509777Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
- Weill Cornell Medicine, New York
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT06274554BOOM-IBD2 Pivotal Clinical Trial
- Northwell Health North Shore University Hospital, Manhasset
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Menerima peserta
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT06571669Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- New York University, New York
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07237516Social Determinants of Health, Medication Use, and Quality of Life in Inflammatory Bowel Disease
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore Hutchinson Campus, The Bronx
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06266663Low Dose IL-2 for the Treatment of Crohn's Disease
- Mount Sinai, New York
Menerima pesertaFase 1/2
Usia 12 hingga 80 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT04263831Autologous Stem Cell Transplant for Crohn's Disease
- Icahn School of Medicine at Mount Sinai, New York
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Jul 2026 · NCT03219359Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Cohen Children's Medical Center of NY, Lake Success
- Columbia University Medical Center, New York
Menerima pesertaFase 4
Usia 6 hingga 17 · Semua jenis kelamin · Diperbarui 27 Mei 2026 · NCT05781152Impact of Morning Light Therapy in IBD
- Mount Sinai Hospital, New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT07207200A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, New York
- Mirador Therapeutics Selected Site, Rochester
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 12 Mar 2026 · NCT07113522Pre-operative Nutrition for Elective Resection Surgery in Inflammatory Bowel Disease
- NYU Langone Health, New York
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT06309017Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation
- Icahn School of Medicine at Mount Sinai, New York
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Jan 2026 · NCT06001450Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- New York University, New York
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Mei 2025 · NCT06750731Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.